{"id":"valtoco-nasal-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasal irritation"}]},"_chembl":{"chemblId":"CHEMBL2094006","moleculeType":"Small molecule","molecularWeight":"702.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diazepam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor in the central nervous system, reducing neuronal excitability. The intranasal formulation allows rapid absorption through the nasal mucosa, achieving faster onset of action compared to oral or rectal routes, making it suitable for acute seizure management.","oneSentence":"Valtoco is a nasal spray formulation of diazepam that rapidly delivers the benzodiazepine to the systemic circulation to provide fast-acting seizure relief.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:09.811Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute seizure clusters or breakthrough seizures in patients with epilepsy"}]},"trialDetails":[{"nctId":"NCT06346262","phase":"PHASE4","title":"Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2024-03-05","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT02663999","phase":"PHASE1","title":"A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2016-01","conditions":"Healthy","enrollment":15},{"nctId":"NCT02313337","phase":"PHASE4","title":"The Comparison of Different Administration Routes of Pediatric Premedication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2014-12","conditions":"Anesthesia","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Valtoco Nasal Product","genericName":"Valtoco Nasal Product","companyName":"University Hospitals Cleveland Medical Center","companyId":"university-hospitals-cleveland-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valtoco is a nasal spray formulation of diazepam that rapidly delivers the benzodiazepine to the systemic circulation to provide fast-acting seizure relief. Used for Acute seizure clusters or breakthrough seizures in patients with epilepsy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}